Histogenics Corporation (HSGX) – Analysts’ Weekly Ratings Updates

Histogenics Corporation (NASDAQ: HSGX) has recently received a number of price target changes and ratings updates:

  • 9/9/2017 – Histogenics Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 9/7/2017 – Histogenics Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 9/1/2017 – Histogenics Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $2.00 price target on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 8/23/2017 – Histogenics Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 8/22/2017 – Histogenics Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 8/15/2017 – Histogenics Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
  • 8/14/2017 – Histogenics Corporation was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/11/2017 – Histogenics Corporation was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/11/2017 – Histogenics Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $4.00 price target on the stock. They wrote, “We highlight that momentum in patient enrollment accelerated in the Q2 with a record of 17 patients enrolled in the month of June and a total of 30 in the quarter. Furthermore, the company reiterated its expectations to deliver one-year data by the end of Q3/18, supporting its BLA filing shortly thereafter, and commercial launch of NeoCart as early as mid-2019. In Japan, management highlighted an agreement with the Japan PMDA regarding a regulatory pathway for the Japanese market, which will revolve around a small, 30- patient, one-year trial comparing NeoCart to microfracture treatment. The trial will be supplemented by US Phase 3 trial data, and Histogenics is currently exploring Japanese partnership opportunities to support the trial with hopes of finagling a partnership by YE/17. Of note, Histogenics hopes its Japanese partnership will provide the company with additional capital. We are encouraged by the progress in Japan and anticipate the geography could be a meaningful market for Histogenics’ long-term success. Investment highlights Reiterated expectations to deliver one-year NeoCart Phase 3 data by the end of Q3/18, supporting BLA filing shortly thereafter, and commercial launch of NeoCart in H2/19. Strengthened commercial management team with the appointment of Donald Haut, PhD as chief business officer. Dr.””

Histogenics Corporation (NASDAQ HSGX) traded up 4.279% during mid-day trading on Wednesday, hitting $2.125. 199,945 shares of the company were exchanged. The company’s 50-day moving average is $1.84 and its 200 day moving average is $1.76. The company’s market capitalization is $47.79 million. Histogenics Corporation has a 12-month low of $1.45 and a 12-month high of $3.64.

Histogenics Corporation (NASDAQ:HSGX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. During the same quarter in the prior year, the company posted ($0.61) EPS. Analysts expect that Histogenics Corporation will post ($1.09) EPS for the current year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply